Bharat Bio, Thomas Jefferson varsity to pursue Covid-19 vaccine candidate

Bharat Bio, Thomas Jefferson varsity to pursue Covid-19 vaccine candidate
By: ET GM Posted On: May 20, 2020 View: 15

Bharat Bio, Thomas Jefferson varsity to pursue Covid-19 vaccine candidate

HYDERABAD: Vaccine manufacturer Bharat Biotech announced signing an exclusive agreement with Thomas Jefferson University of Philadelphia to develop a new vaccine candidate for COVID-19 invented at Jefferson.

The novel vaccine was developed using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins, said the Hyderabad headquartered vaccine maker.

The vector used in this new COVID-19 vaccine under accelerated development program is a deactivated rabies vaccine that is known to produce a strong immune response and is approved for the whole population including children and pregnant women, it said.

In January this year, infectious diseases expert Professor Matthias Schnell’s lab developed the vaccine, and has recently completed preliminary tests in animal models. According to Bharat Bio, the vaccine showed a strong antibody response in mice receiving the vaccine, and the researchers are currently testing whether vaccinated animals are protected from SARS-CoV-2 infection with results expected in the next month.

“Since we know the immune system reacts to the rabies vaccine with a strong response when we add the coronavirus component, we expect to see that level of protection, and immune memory, carry over to the SARS-CoV-2 viral protein as well,” saysProf. Schnell.

Bharat Biotech gains exclusive rights to develop, market and deliver Jefferson’s vaccine under the agreement across the world excluding countries such as USA, Europe and Japan, where Jefferson continues to seek partners. With support from India’s Department of Biotechnology, Bharat Biotech aims to get into human trials as soon as December 2020.

“Our partnership with Bharat Biotech will accelerate our vaccine candidate through the next phases of development,” said Prof Schnell, a coronavirus expert who directs The Jefferson Vaccine Institute and chairs Jefferson’s Department of Microbiology and Immunology. “We will be able to complete animal testing and move to phase-I clinical trial rapidly.”

Bharat Biotech chef executive Dr Krishna Mohan said, “Bharat Biotech is pleased to collaborate with Thomas Jefferson, USA towards developing a new vaccine for COVID-19 using an inactivated rabies vector platform. We are particularly excited about this technology since the basic proof of concept has been established while using it for other pandemic infectious diseases.”

  Contact Us

Botawala Chambers , Fort-Mumbai

Tel : + (91) - 8484924178
Mail :
Business Hours : 9:30 - 5:30


Dailyagronews is a dedicated platform for Exclusive Agriculture News , Now stay in touch with latest happenings in Agriculture . This site is a work of team of technocrafts wanted to help the farming community by contributing something helpful to them. Join this unique platform by contributing the agro news , we will be happy to make it viral